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Abstract
Background: Hospital-associated infections (HAIs) are associated with a considerable burden of disease and direct
costs greater than $17 billion. The pathogens that cause the majority of serious HAIs are Enterococcus faecium,
Staphylococcus aureus, Clostridium difficile, Klebsiella pneumoniae, Acinetobacter baumannii, Pseudomonas aeruginosa,
and Enterobacter species, referred as ESCKAPE. We aimed to determine the amount of funding the National
Institute of Health (NIH) National Institute of Allergy and Infectious Diseases (NIAID) allocates to research on
antimicrobial resistant pathogens, particularly ESCKAPE pathogens.
Methods: The NIH Research Portfolio Online Reporting Tools (RePORT) database was used to identify NIAID
antimicrobial resistance research grants funded in 2007-2009 using the terms “antibiotic resistance,” “antimicrobial
resistance,” and “hospital-associated infection.”
Results: Funding for antimicrobial resistance grants has increased from 2007-2009. Antimicrobial resistance funding
for bacterial pathogens has seen a smaller increase than non-bacterial pathogens. The total funding for all ESKCAPE
pathogens was $ 22,005,943 in 2007, $ 30,810,153 in 2008 and $ 49,801,227 in 2009. S. aureus grants received
$ 29,193,264 in FY2009, the highest funding amount of all the ESCKAPE pathogens. Based on 2009 funding data,
approximately $1,565 of research money was spent per S. aureus related death and $750 of was spent per C.
difficile related death.
Conclusions: Although the funding for ESCKAPE pathogens has increased from 2007 to 2009, funding levels for
antimicrobial resistant bacteria-related grants is still lower than funding for antimicrobial resistant non-bacterial
pathogens. Efforts may be needed to improve research funding for resistant-bacterial pathogens, particularly as
their clinical burden increases.
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Background
The National Institutes of Health (NIH) has been suc-
cessful over the past 60 years in funding research that
has greatly advanced modern medicine. However, given
limited resources, many have begun to question how
these research funds are allocated to various diseases
[1-3]. The NIH has listed five major criteria for the allo-
cation of research funds: public health needs, the
scientific quality of research, the probability of success,
the maintenance of a diverse portfolio, and the mainte-
nance of an adequate scientific infrastructure [4]. While
the Institute of Medicine panel has embraced these cri-
teria as an appropriate framework for funding, they also
concluded that the NIH does not adequately describe
how public health need is assessed, and recommended
the use of burdens and costs of diseases in strengthening
their assessment and use of health data [5].
The relationship between burden of disease and
research funding is an important metric to consider
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when determining funding priorities that impact public
health. Hospital-acquired infections (HAIs) are asso-
ciated with a considerable burden of disease. The Cen-
ters for Disease Control and Prevention (CDC)
estimates that each year in the United States there are
about 1.7 million HAIs and 99,000 associated deaths.
[6] The mean direct costs of HAIs (in 2005 dollars)
range from $1,257 per case for catheter-associated urin-
ary tract infections to $22,875 per case for ventilator-
associated pneumonia [7].
The pathogens that cause the majority of serious HAIs
are Enterococcus faecium, Staphylococcus aureus, Kleb-
siella pneumoniae, Acinetobacter baumannii, Pseudomo-
nas aeruginosa, and Enterobacter species- commonly
referred to as ESKAPE bacteria [8]. Recently though,
Clostridium difficile has emerged as an important noso-
comial pathogen. In 2007, C. difficile was ranked as one
of the 20 leading causes of death for people aged 65 and
older [9]. Thus, this study has included C. difficile in the
ESKAPE bacteria definition, henceforth known as ESCK-
APE bacteria.
The aim of this study was to determine the amount
of funding the NIH’s National Institute of Allergy and
Infectious Diseases (NIAID) allocates to research on
antimicrobial nosocomial pathogens, particularly
ESCKAPE pathogens and to compare this funding to
the burden of disease caused by two ESCKAPE
pathogens.
Methods
Identifying Grants Using NIH RePORT Database
The NIH Research Portfolio Online Reporting Tools
(RePORT) database was used to identify NIH-funded
research grants. Searches were done during the month
of November 2011 among all available fiscal years for
retrospective grant funding data using the search terms
“antibiotic resistance,” “antimicrobial resistance,” and
“hospital-associated infection” that included the National
Institute of Allergy and Infectious Diseases (NIAID) as the
administration or funding agency. Over 11,000 grants
were screened to exclude duplicates from the search
terms.
Classifying Grants into Pathogen Categories
Abstracts of the remaining grants were viewed in detail
and categorized by the pathogen of interest (e.g. bac-
teria, virus, fungi, parasites). If the pathogen was classi-
fied as bacteria, the grant was further analyzed for
drug resistance and type of bacterial species. If unclear,
the grant was reviewed by a second reviewer. Bacterial
grants were then classified as hospital-associated and
non-hospital-associated based on the type of pathogen.
Special emphasis was placed on ESCKAPE bacteria.
Mortality funding
National mortality data for MRSA and C. difficile were
obtained from prior publications by the CDC’s Active
Surveillance Core and National Vital Statistics [9,10].
Funding amounts for MRSA and C. difficile were then
divided by the most recent national mortality statistics
to estimate the dollar amount funded per death for each
pathogen.
Results
Regardless of the search term, total amount and number
of grants funded by the NIAID have increased during
the study period. From FY2007 to FY2008 the total
amount increased by approximately 82% and further
increased by 22% from FY2008 to FY2009. The number
of grants funded from FY2007 to FY2009 increased by
58% and then 16%. Consequently, the average funds per
grant steadily increased as well. This trend seems to fol-
low the total NIAID budget (Table 1).
As mentioned, the funding trend for antimicrobial
resistance studies during FY2007 through FY2009 shows
a large increase during the first year and then a smaller
increase in the subsequent year. This trend is also
observed when the grants are stratified by pathogen of
interest; non-bacterial (> 90% being viruses) and bacter-
ial (combination of ESCKAPE, Mycobacterium, and
other bacterial pathogens) (Figure 1). Both groups show
similar overall trend, consistent with the total funds
trend, however the funding for bacterial pathogens has
seen a smaller increase than non-bacterial pathogens
during FY2008 to FY2009.
The total funding for all ESKCAPE pathogens was $
22,005,943 in FY2007, $ 30,810,153 in FY2008 and $
49,801,227 in FY2009. Staphylococcus aureus grants
received $ 29,193,264 in FY2009, the highest funding
amount of all the ESCKAPE pathogens. Enterobacter
species received $ 378,005 in FY2009, the lowest amount
of all the ESCKAPE pathogens. In FY2009, Enterococcus
faecium, Klebsiella pneumoniae, Acinetobacter bauman-
nii, Pseudomonas aeruginosa, and Clostridium difficile
grants received $602,635, $1,412,872, $2,329,872,
$11,708,364, and $4,778,850 respectively. The funding
trend for all ESCKAPE pathogens increased during the
three year study period, except Enterobacter species due
to lack of data for years prior to 2009 (Figure 2). Total
grant funding increased by 40% for the first year and
increased by 61% the following year. The majority of the
grant funding was related to Staphylococcus aureus,
which increased approximately 2.5 times from FY2007 to
FY2009.
In 2005, there were an estimated 18,650 deaths among
people infected with MRSA [10]. Based on FY2009
funding data for Staphylococcus aureus, approximately
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$1,565 of research funding was spent per death. In 2007,
6,372 people infected with Clostridium difficile died [9].
Based on FY2009 funding data, approximately $750 of
research funding was spent per C. difficile death. Accord-
ing to the NIH RePORT database, NIAID funding for
HIV/AIDS was estimated to be $1.302 billion. This is
similar to previous reports of $1.244 billion of NIAID
funds allocated to HIV/AIDS in 2009. [11] Roughly
17,000 - 18,000 HIV deaths occur annually in the U.S
[12]. Based on these rough numbers approximately
$72,000 - $76,000 per HIV/AIDS death was spent for
research.
Our search results were compared to the grants listed
in the “Antimicrobial Resistance” category of the NIH
Table 1 Number of NIAID Grants and Amounts by Search Term and Year
Search Term Fiscal Year (FY) Total Amount ($) Total Number of Grants Amount per Grant ($)
Antibiotic Resistance 2007 67,860,927 199 341,010
2008 72,972,153 223 327,229
2009 101,623,126 282 360,366
Antimicrobial Resistance 2007 6,817,017 24 284,042
2008 136,111,065 241 564,776
2009 138,905,976 242 573,992
Hospital-Associated Infection 2007 105,574,441 183 576,910
2008 118,117,691 176 671,123
2009 158,118,571 216 732,030
Combined 2007 180,252,385 406 443,971
2008 327,200,909 640 511,251
2009 398,647,673 740 538,713
Approximate NIAID budget 2007 4,366,000,000
2008 4,561,000,000
2009 4,569,000,000
No duplicate grants in each search term
Figure 1 NIAID Funding for Antimicrobial Resistance Stratified by Non-bacterial Grants vs. Bacterial Grants.
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RePORT Research, Condition, and Disease Categories
(RCDC) (http://report.nih.gov/rcdc/categories/) (Figure 3).
Unlike our search, the NIH grants listed in the RCDC
Antimicrobial Resistance category only covered the search
term “Antimicrobial resistance” for FY2008 and FY2009.
However, the overall results are similar; from FY2008 to
FY2009 general funding in the RCDC Antimicrobial Resis-
tance category increased by 25%, ESCKAPE pathogen
funding increased by 24%, and about half of the funding is
devoted to bacterial pathogens. The results that we
reported are slightly different from the RCDC results
because we included the “Hospital-associated infection”
search term, which would have added more non-resistant
bacterial grants to our search results.
Using NIH RePORTER we also attempted to evaluate
grants funded by other agencies for ESCKAPE pathogens
during the FY2007 - 2009. We focused on three major
agencies; CDC, the Agency for Healthcare Research and
Quality (AHRQ), and Veteran’s Health Administration
(VHA). No information was obtained for AHRQ and no
funding amounts were listed for VHA. During the search,
there were only four grants listed for VHA in the
FY2009. Nine grants related to ESCKAPE pathogens
were funded by the CDC in FY2007-08 and decreased to
six grants in FY2009. Funding amounts decreased over
the same period from approximately $3 million in
FY2007 to approximately $1.9 million in FY2009.
Discussion
Currently, the antibiotic era is threatened by the conver-
gence of three adverse circumstances: high levels of anti-
bacterial resistance among important pathogens, a
dwindling supply of novel classes of antibacterials, and a
dramatic reduction in the number of pharmaceutical
companies engaged in the discovery and development of
antibacterial agents. [13] While 10 new classes of antibio-
tics were discovered from the 1930s to the 1960s, only
two new classes have been approved since 1970 [13]. In
addition, due to the relatively unfavorable return on
investment, pharmaceutical companies have been steer-
ing away from engaging in antibiotic-drug discovery
[14,15].
The response to the public-health crisis of antibacterial
resistance could be similar to the strategies used to coun-
ter HIV. For the past 30 years, NIH-funded research has
made great progress in implementing various prevention
measures, including reducing the transmission rate of
perinatal HIV, HIV drug development and treatment, and
a potential vaccine [16,17]. In 2009, the NIH awarded
$1.302 billion in research funding for HIV/AIDS. [NIH
Figure 2 NIAID Funding by ESCKAPE Pathogen.
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Research Portfolio Online Reporting Tools (RePORT)
http://projectreporter.nih.gov]. As a marker of NIH’s HIV
research success, in the U.S. in 2005, there were more
deaths attributed to MRSA infections than attributable to
HIV/AIDS [18].
The NIH is not blind to the emerging problem of
antibiotic resistance, and in response created the ‘anti-
microbial resistance’ funding category. However, the
title ‘antimicrobial’ includes viruses and parasites as well
as antibiotic-resistant bacteria. Even though funding
continues to increase in the antibiotic-resistance cate-
gory, we found that only half of the funding is going to
antibacterial research and the large increases in funding
have targeted non-bacterial pathogens. The ESCKAPE
pathogens are inherently different compared to viruses
such as HIV and other pathogens such as Mycobacter-
ium tuberculosis, thus they require specific attention [8].
From a mortality stand point, even though in the United
States MRSA and HIV may be on par with each other,
the research dollars invested shows a stark difference
($1,565 vs. $72,000 per death) when only considering
NIAID research dollars. Considering other agency dol-
lars, not to mention funding from pharmaceutical com-
panies, will only widen this gap further. In order to have
the hope in making the tremendous advances seen in
HIV research, antibacterial research would need
increased backing. Separate RCDC funding categories in
“Antibacterial Resistance” and “Hospital-acquired infec-
tions” might be needed in order to highlight the need
for more research dollars and attention to this ongoing
crisis.
Our estimates may be limited since we only assessed
NIAID funding, and not other institutes in the NIH or
other agencies such as the CDC, the Agency for Health-
care Research and Quality (AHRQ), or Veteran’s Health
Administration. However, NIAID is the major agency
within NIH that focuses on antimicrobial research. NIAID
currently spends $800 million per year in antimicrobial
research, which includes $200 million annually in research
to better understand the causes, consequences, and treat-
ments of drug resistance [19]. CDC has allocated approxi-
mately $17 million for antimicrobial resistance, which is
mainly for preparedness, detection, and control purposes
not for research [20]. Congress appropriated $5 million for
MRSA and related hospital-associated infections in 2007-
2008, then in 2009 $17 million ($8 million for MRSA and
the remaining for other HAI) to AHRQ [21]. The VHA
receives approximately $500 million in medical research
but most of the funding is divided among other projects
such as Gulf War illnesses, genomics, prosthetics, diabetes,
and heart disease [22]. Very little is given to antimicrobial
research. The combined total from these various agencies
Figure 3 Funding from NIH Research, Condition, and Disease Categories Category “Antimicrobial Resistance” (FY2008 and FY2009).
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is a fraction of what the NIAID funds, thus our research is
representative of the funding situation of antimicrobial
research. Our data may be limited by missing information
in the NIH RePORT website. However, this is the best
public access source of NIAID research funding and
should be up to date for FY2007-2009. Finally, our
estimates of the amount of research funding spent per
S. aureus or C. difficile death may be an overestimate or
underestimate since we do not have mortality data from
FY2009. However, the number of deaths associated with
MRSA or C. difficile should not have significantly declined
because no new antibiotics have become available since
2005.
In summary, although it is impressive that the funding
for ESCKAPE pathogens has increased over a relatively
short period of time, funding levels for antimicrobial-resis-
tant bacteria related grants is still lower than funding for
antimicrobial-resistant, non-bacteria related grants. Annual
NIAID funding for MRSA and C. difficile infections
remains below $2,000 per death. Steps should be made in
order to match the funding for ESCKAPE pathogens to
their disease burden. If we are to have any hope in holding
back the tide of antibacterial resistant pathogens as a cause
of community and hospital-acquired infections, it is likely
that funding will have to increase to the levels successfully
employed in HIV-related research during the past three
decades. NIAID should be encouraged to make a clear
public commitment to increasing funding for the develop-
ment of new antibacterials and expand the knowledge base
around infection prevention.
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